Halozyme Therapeutics, Inc. filings document the company's drug-delivery business, royalty-based collaboration model, governance actions and capital-market disclosures. 8-K reports cover financial results and guidance, executive officer appointments and compensation arrangements, bylaw amendments, and annual meeting voting results.
Proxy materials describe board elections, executive compensation, equity awards, auditor ratification and stockholder voting mechanics. Filings also provide formal disclosure around ENHANZE, Hypercon and Surf Bio technology portfolio updates, partnered commercial products, and acquisition-related operating updates when reported by the company.
Bernadette Connaughton, a director of Halozyme Therapeutics (HALO), reported sales of common stock on 09/02/2025 executed under a pre-established Rule 10b5-1 trading plan adopted on 05/29/2025. The Form 4 shows three sell transactions: 100 shares at $71.71, 2,977 shares at a weighted-average $73.618 (range $72.91–$73.89), and 923 shares at a weighted-average $74.111 (range $73.95–$74.38). After these disposals the reporting person beneficially owned 46,952 shares, held directly.
Halozyme Therapeutics (HALO) notice reports a proposed sale of 8,829 shares of common stock through Morgan Stanley Smith Barney LLC on 09/02/2025 on the NASDAQ. The shares were originally acquired as Restricted Stock Units from the issuer on 04/30/2021. The filing shows an aggregate market value of $645,841.35 for the shares and lists 116,966,000 shares outstanding for the issuer. No other sales in the past three months are reported, and the filer affirms they are not aware of undisclosed material adverse information.
Helen Torley, President and CEO and a director of Halozyme Therapeutics (HALO), exercised a total of 60,000 stock options at an $8.11 exercise price and concurrently sold the resulting 60,000 common shares over three days. The sales were executed at weighted-average prices reported in ranges between $62.54 and $64.96 per share, and the Form reports 733,719 shares beneficially owned by the reporting person following these transactions.
The filings state the transactions were made under a written Rule 10b5-1 trading plan adopted March 21, 2025, and that the sold shares were acquired upon exercise of options with ten-year terms expiring in February 2026. The underlying options were originally granted February 3, 2016, with a four-year vesting schedule.
Halozyme Therapeutics (HALO) President and CEO Helen Torley executed a series of pre-planned transactions under a Rule 10b5-1 trading plan established on March 21, 2025. The transactions occurred over three consecutive days:
- June 20, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares at avg. $52.96
- June 23, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares at avg. $52.57
- June 24, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares (4,489 at avg. $53.11 and 15,511 at avg. $53.91)
Following these transactions, Torley holds 733,719 shares directly and 316,569 options at $8.11 strike price expiring February 3, 2026. The options were originally granted in 2016 with a 4-year vesting schedule. All transactions were executed under a pre-established 10b5-1 trading plan, demonstrating compliance with insider trading regulations.